Tolvaptan in autosomal dominant polycystic kidney disease: Three years' experience

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 10, 2011, Pages 2499-2507

  Higashihara, Eiji ^a   Torres, Vicente E ^b   Chapman, Arlene B ^c   Grantham, Jared J ^d   Bae, Kyongtae ^e   Watnick, Terry J ^f   Horie, Shigeo ^g   Nutahara, Kikuo ^g   Ouyang, John ^h   Krasa, Holly B ^h   Czerwiec, Frank S ^h  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Mayo Clinic College of Medicine   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TOLVAPTAN;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIHYPERTENSIVE THERAPY; ANXIETY; ARTHRALGIA; ARTICLE; BACKACHE; BRAIN ARTERY ANEURYSM; BRONCHITIS; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; CONTROLLED STUDY; CONTUSION; COUGHING; CREATININE BLOOD LEVEL; DEHYDRATION; DENTAL CARIES; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DRY SKIN; DYSPEPSIA; DYSPNEA; ECZEMA; EROSIVE GASTRITIS; ERYTHEMA; EYE SWELLING; FATIGUE; FEMALE; GASTRITIS; GENDER; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEART PALPITATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPERURICEMIA; HYPOPHYSIS TUMOR; HYPOTENSION; INSOMNIA; INTERVERTEBRAL DISK HERNIA; KERATITIS; KIDNEY DYSFUNCTION; KIDNEY POLYCYSTIC DISEASE; KIDNEY SIZE; LIMB PAIN; MAJOR CLINICAL STUDY; MALAISE; MALE; MUSCLE INJURY; MUSCLE SPASM; MUSCULOSKELETAL PAIN; NAUSEA; NECK PAIN; NOCTURIA; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PHOSPHATE BLOOD LEVEL; POLLAKISURIA; POLYDIPSIA; POLYURIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFLAMMATION; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SPONDYLOSIS; STOMACH POLYP; SUBARACHNOID HEMORRHAGE; THIRST; THORAX PAIN; TINEA PEDIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; URIC ACID BLOOD LEVEL; URINARY TRACT INFECTION; VASOPRESSIN BLOOD LEVEL; VERTIGO; VIRAL UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ADOLESCENT; ADULT; BENZAZEPINES; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HORMONE ANTAGONISTS; HUMANS; JAPAN; KIDNEY; MALE; MIDDLE AGED; NORTH AMERICA; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PROSPECTIVE STUDIES; RECEPTORS, VASOPRESSIN; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80053904548     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03530411     Document Type: Article

References (18)

1. Grantham JJ: Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med 359: 1477-1485, 2008
2. Gabow P: Autosomal dominant polycystic kidney disease. N Engl J Med 329: 323-342, 1993
3. Dalgaard OZ: Bilateral polycystic disease of the kidneys: A follow-up of two hundred and eighty-four patients and their families. Acta Med Scand 328: 1-255, 1957
4. Torres VE, Harris PC, Pirson Y: Autosomal dominant polycystic kidney disease. Lancet 369: 1287-1301, 2007
5. Bajwa ZH, Gupta S, Warfield CA, Steinman TI: Pain management in polycystic kidney disease. Kidney Int 60: 1631-1644, 2001
6. Torres VE: Vasopressin in chronic kidney disease: An elephant in the room? Kidney Int 76: 925-928, 2009
7. Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF, Jr, Wetzel LH, Baumgarten DA, Kenney PJ, Harris PC, Klahr S, Bennett WM, Hirschman GN, Meyers CM, Zhang X, Zhu F, Miller JP: Volume progression in polycystic kidney disease. N Engl J Med 354: 2122-2130, 2006
8. Grantham JJ, Chapman AB, Torres VE: Volume progression in autosomal dominant polycystic kidney disease: The major factor determining clinical outcomes. Clin J Am Soc Nephrol 1: 148-157, 2006
9. USDA: Develop biomarkers to aid in the development of therapies for polycystic kidney disease (PKD). In: Key FDA critical path activities under way in 2007. Washington, D.C., U.S. Department of Health and Human Services Food and Drug Administration, June 2008, page 5
10. Klahr S, Levey A, Beck G, Caggiula A, Hunsicke L, Kusek J, Striker G: The effects of dietary protein restriction and bloodpressure control on the progression of chronic renal disease. N Engl J Med 330: 877-884, 1994
11. Ravine D, Gibson RN, Walker RG, Sheffield LJ, Kincaid- Smith P, Danks DM: Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet 343: 824-827, 1994
12. Stevens L, Greene T, Levey A: Surrogate endpoints for clinical trials of kidney disease progression. Clin J Am Soc Nephrol 1: 874-884, 2006
13. Klahr S, Breyer J, Beck G, Dennis V, Hartman J, Roth D, Steinman T, Wang S, Yamamoto M: Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease modification of diet in renal disease study group. J Am Soc Nephrol 5: 2037-2047, 1995
14. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F: Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145: 247-254, 2006
15. Horio M, Imai E, Yasuda Y, Watanabe T, Matsuo S: Modification of the CKD epidemiology collaboration (CDK-EPI) equation for Japanese: Accuracy and use for population estimates. Am J Kidney Dis, 56: 32-38, 2010
16. Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, Levey AS: The effect of a lower target blood pressure on the progression of kidney disease: Long-term follow-up of the modification of diet in renal disease study. Ann Intern Med 142: 342-351, 2005
17. Wang CJ, Creed C, Winklhofer FT, Grantham JJ: Water prescription in autosomal dominant polycystic kidney disease: A pilot study. Clin J Am Soc Nephrol 6: 192-197, 2011
18. Irazabal MV, Torres VE, Hogan MC, Glockner J, King BF, Ofstie TJ, Krasa HB, Ouyang J, Czerwiec FS: Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney Int 80: 295-301, 2011